Author: hkaraman

Insights

Most Favored Nation (MFN) Drug Pricing: Market Access Implications and Manufacturer Preparedness

What Is MFN?

A Most Favored Nation (MFN) drug pricing policy would tie certain U.S. drug prices (most likely within Medicare) to the lowest price paid for the same product in a basket of comparable, economically advanced countries.

Rather than relying solely on domestic benchmarks such as Average Sales Price (ASP), MFN models use international reference pricing (IRP) to cap U.S. reimbursement levels

While MFN is not currently in effect, variations of the policy have been proposed multiple times and remain a recurring theme in federal drug pricing discussions. In a post-IRA environment where Medicare negotiation is already reshaping pricing dynamics, MFN represents a potential next phase of pricing reform.

Why MFN Matters for Market Access

MFN is not simply a pricing policy. It fundamentally changes the interplay between global pricing strategy and U.S. access dynamics.

Historically:

  • U.S. pricing has been largely insulated from international pricing decisions
  • Market access strategy in the U.S. focused primarily on payer mix, contracting, and value demonstration domestically

Under MFN:

  • Global pricing decisions directly influence U.S. reimbursement
  • Ex-U.S. launch sequencing and pricing strategy become U.S. access decisions
  • Market access planning must shift from domestic optimization to global coordination

This creates both operational complexity and strategic risk.

Key Market Access Impacts

1. Global Launch Sequencing Becomes a U.S. Access Lever

If U.S. Medicare reimbursement is pegged to the lowest international price:

  • Early lower-price agreements in EU markets could reduce U.S. reimbursement ceilings
  • Delays in ex-U.S. launches may become more common
  • Manufacturers may prioritize price stability over speed to global access

Market Access Implication:
Launch sequencing, traditionally a commercial strategy decision, becomes a critical component of U.S. access preservation.

2. Increased Pressure on Gross-to-Net Strategy

MFN could effectively cap top-line pricing:

  • Reduced flexibility to offset domestic rebates with higher list prices
  • Potential compression of net revenue if international reference prices are significantly lower
  • Greater scrutiny of contracting structures across both Medicare and commercial segments

Market Access Implication:
Manufacturers will need tighter integration between pricing, contracting, and policy teams to manage cross-market impacts

3. Impact on Medicare Negotiation Leverage

If MFN is layered onto IRA price negotiation:

  • The “maximum fair price” ceiling could be influenced by international pricing floors
  • Negotiation dynamics may shift toward even greater federal leverage
  • Therapeutic classes with strong ex-U.S. HTA pressure (e.g., oncology, immunology) could see disproportionate exposure

Market Access Implication:
Access teams must prepare for negotiations that incorporate international comparators more explicitly and aggressively.

4. Formulary and Utilization Management Ripple Effects

Lower Medicare reimbursement rates could:

  • Change buy-and-bill economics in Part B
  • Affect provider margin and prescribing behavior
  • Influence payer formulary positioning in Part D

If margins compress:

  • Providers may prefer alternative therapies with better economics
  • Access hurdles may increase if plans attempt to offset reimbursement compression elsewhere.

Market Access Implication:
Manufacturer field reimbursement and provider engagement strategies will need to adapt quickly

Manufacturer Decision-Making Under MFN Risk

Even before implementation, MFN risk affects strategic planning. Manufacturers should be incorporating MFN into scenario modeling now

1. Portfolio Risk Stratification

Companies should assess:

  • Which assets are most exposed to international price referencing?
  • Which therapeutic areas face the largest EU-U.S. price deltas?
  • Which products are most Medicare-dependent?

This enables:

  • Prioritized mitigation planning
  • Revenue-at-risk modeling
  • Earlier lifecycle management interventions

2. Integrated Global Pricing Governance

MFN requires tighter alignment across:

  • U.S. market access
  • Global pricing & reimbursement
  • Government affairs
  • Legal and compliance

Decisions that were once siloed (e.g., a German price agreement) may have direct downstream U.S. impact

Prepared organizations will:

  • Establish formal cross-market price governance committees
  • Model international pricing agreements before execution
  • Create scenario playbooks for reference price compression

3. Enhanced Economic Value Demonstration

As pricing ceilings tighten, value demonstration becomes even more critical:

  • Stronger real-world evidence (RWE)
  • More robust health economic modeling
  • Outcomes-based contract readiness
  • Clear differentiation from therapeutic alternatives

Under MFN, margin compression increases the importance of maintaining favorable access tiers and minimizing utilization restrictions.

4. Contracting Innovation and Risk Sharing

If top-line pricing flexibility narrows:

  • Manufacturers may shift toward outcomes-based agreements
  • Indication-specific pricing may gain traction
  • Population health-based contracting could become more common

Access teams should be developing infrastructure now to support:

  • Data collection and analytics
  • Outcomes measurement
  • Performance-based reimbursement models

5. Scenario Planning and Financial Modeling

MFN preparedness requires:

  • Modeling various international basket configurations
  • Estimating price floors under different country mixes
  • Stress-testing gross-to-net assumptions
  • Evaluating provider economics impact (especially in Part B)

This modeling should inform:

  • Investor communications
  • Portfolio prioritization
  • Pipeline investment decisions

Preparedness Checklist for Market Access Teams

Manufacturers should consider the following actions:

Strategic Planning

☐ Conduct MFN exposure modeling by product

☐ Quantify Medicare revenue at risk

☐ Map international price differentials across key markets

Governance

☐ Formalize cross-market pricing review processes

☐ Establish escalation protocols before signing major ex-U.S. agreements

☐ Align U.S. and global access leadership

Evidence & Value

☐ Strengthen RWE generation plans

☐ Prepare enhanced HEOR dossiers

☐ Expand outcomes-based contracting readiness

Operational Readiness

☐ Assess provider reimbursement impact

☐ Update field reimbursement training

☐ Develop payer communication strategies

MFN may or may not materialize in its current form, but the direction of travel in U.S. drug pricing policy is clear: increased scrutiny, global benchmarking, and tighter reimbursement controls. Organizations that wait for final rules before acting risk being structurally unprepared.

Is your portfolio exposed to MFN risk?

At Danforth Health, we work with manufacturers to model policy exposure, align global and U.S. pricing strategy, pressure-test access assumptions, and build practical readiness plans. If MFN, or broader international reference pricing, would materially affect your portfolio, now is the time to assess your exposure and build a coordinated response.

Schedule a conversation with our experts to evaluate your MFN exposure and build a readiness strategy.

Insights

AI in Clinical Outsourcing: What’s Signal, What’s Noise? 

Written by Rene Stephens, Managing Director, Clinical Business Operations, Danforth Health  

AI in clinical development is everywhere right now. Headlines promise transformation. Vendors promise acceleration. Teams are running pilots. 

But beneath the noise, where does the industry actually stand? 

To better understand the reality, Danforth Health conducted a focused industry pulse survey both before the 2026 SCOPE Summit Conference and during a live panel discussion with Outsourcing, Clinical Operations, and healthcare Innovation experts on The Impact of AI on Outsourcing and Clinical Trial Execution. The findings provide a candid snapshot of adoption, constraints, and where real value is (and isn’t) emerging.  

View the survey results here and continue reading for the 5 biggest takeaways… 

1. AI Adoption Is Real — but Still Fragmented 

Survey respondents confirmed that AI is no longer theoretical in clinical development, yet enterprise-wide adoption remains the exception, not the rule. 

  • 22% report actively using AI in a subset of trials 
  • 30% are implementing or formally allowing AI use 
  • 37% are still evaluating 

Nearly 90% of organizations are somewhere on the adoption curve, but most remain in pilot mode, functional silos, or narrowly defined use cases rather than scaled transformation. 

The takeaway: AI credibility has arrived. Operational maturity has not. 

2. Deployment Is Concentrated Where Risk Is Measurable 

Where AI is being deployed, the survey shows strong clustering around activities with: 

  • High data density 
  • Clear quality metrics 
  • Auditable outputs 

Respondents reported AI usage primarily in: 

  • Data capture and quality oversight 
  • Protocol design and optimization 
  • Patient population and cohort identification 
  • CSR preparation and submission support 

Adoption is split between internally built tools and vendor/CRO-provided solutions, raising a strategic question many sponsors are still debating:

Is AI a capability to own, or a service to buy?  

3. The Business Case Is Speed — Not Headcount Reduction 

One of the clearest signals from both survey responses and the panel discussion: 

AI’s value is being measured in cycle-time compression, not FTE elimination. 

External benchmarks point to an average six-month reduction in development timelines per asset driven by: 

  • Improved protocol feasibility 
  • Faster cohort identification 
  • Earlier quality signal detection 

Sponsors are not viewing AI as a replacement for CROs or clinical teams. Instead, it’s emerging as an execution accelerator, a tool to reduce rework, friction, and downstream risk. 

4. Governance, Not Technology, Is the Primary Bottleneck 

The biggest obstacles aren’t algorithmic; they’re organizational and are likely more difficult to overcome without a deliberate approach to change management.  

Transparent positioning of the impact to current and future functions, both positive and potentially negative, and honest discussions with key stakeholders to address changes to operating processes and team roles, among others, are key considerations for POC pilots as well as full implementation. 

Despite optimism, respondents expressed clear confounders to value: 

  • Unclear ownership across Clinical Ops, IT, Data Science, and Procurement 
  • Variability in CRO AI maturity and transparency 
  • Questions around validation, auditability, and regulatory defensibility 

At the same time, ICH E6(R3) and the FDA Diversity Action Plan (effective January 1, 2026) will increasingly force sponsors to integrate AI into risk-based quality management and enrollment analytics, whether they feel operationally ready or not. 

In short: AI adoption is no longer optional, but unmanaged adoption is risky. 

5. 2026–2027 Will Separate Experimenters from Operators 

The survey reinforces a forward-looking conclusion: 

  • Organizations can realize measurable gains in speed and predictability, and possibly see cost savings when AI is embedded into core trial design and operations (i.e., feasibility, site ID, data management, safety reporting, etc.) 
  • Those that treat AI as an “innovation sidecar” risk falling behind, even if they run more pilots 

This is less about tools and more about operating model design: 

  • Sponsor-led vs. CRO-led AI 
  • Centralized vs. functional deployment 
  • Governance that enables scale without slowing execution 

My Thoughts? 

This industry pulse survey’s results tell a clear story: 

AI in clinical trials has crossed the credibility threshold—but not the execution threshold. 

The next phase will be defined less by better algorithms and more by better integration: 

  • Into outsourcing strategy 
  • Into vendor governance 
  • Into clinical operating models 

That is where real competitive advantage will be created. 

If your team is navigating similar decisions around AI adoption and governance, we’d welcome the opportunity to compare perspectives. Reach out for a brief follow-up discussion to explore how your approach aligns with broader industry trends.   

Insights

Commercial Planning: Building the Right Launch Team & Governance Model

Expert insights from Asymmetry Group, a Danforth Health Company

Product launches are amongst the most complex undertakings for biopharma companies—and there’s no shortcut to success. No matter how strong your strategy or detailed your plan, success ultimately depends on people. If you don’t have the right team in place, even the best-designed launch will fall short. That’s why launch governance and team structure aren’t just operational necessities; they’re strategic levers. Organizations that invest in building a high‑performing launch team and a governance model tailored to their unique needs don’t just execute—they create a competitive advantage.

Several considerations will shape your launch team structure and governance—and directly influence who you select, how the team operates, and what support they’ll need:

1) Launch Experience 

Is this your company’s first launch? How much launch experience exists within your organization?

Implications: Internal experience will impact the level of expertise required on the team, whether you need to bring in external support, and how much structure and oversight your governance model must provide.

2) Desired Launch Team Dynamics

To what extent do you expect your team to operate as an integrated, cross‑functional group? Is this consistent with your current culture?

Implications: Your desired team dynamic will shape role selection, behavioral expectations, and whether new ways of working are needed to enable strong cross‑functional collaboration. Even if you have a highly experienced launch team, it’s likely the first time THIS TEAM is launching together.

3) Organizational Decision-Making

How does your organization collaborate and make decisions? Is authority centralized or shared across empowered teams? Are decisions made quickly or more slowly?

Implications: Existing decision-making patterns will inform governance design—defining authority levels, escalation pathways, meeting cadence, and required functional representation to maintain momentum. And then it’s up to the organization to live these decisions to create trust and efficiency.

4) Partnerships 

Are external partners involved in the launch? What is the structure of the relationship, and how could it affect planning and execution?

Implications: Partnership arrangements will influence team composition, require clearly defined roles and responsibilities, and may necessitate additional coordination or joint governance mechanisms.

    While there’s no single approach to structuring your launch team and governance, four best practices consistently position organizations for success:

    1) Appoint a Launch Lead Who Bridges Strategy and Execution

    This role varies by company and launch, but the Launch Lead must flex between strategic and execution‑focused work while maintaining a strong cross‑functional lens. Launch success requires alignment across all functions—not the efforts of just one or two teams.

    2) Establish a Small, Expert Launch Management Team (LMT) to Drive Progress 

    Typically composed of the Launch Lead and a few launch‑experienced resources, the LMT drives critical work: shaping strategy, coordinating across teams, tracking progress, and flagging risks. Acting as the “quarterback” of the launch, the LMT ensures visibility, timely communication, and cross‑functional alignment.

    3) Create a Lean, Empowered Governance Structure that Can Scale

    Your model should include a Core Launch Team, Extended Launch Team, Steering Committee, and functional working teams. Core Launch Team members—one per key function—must be empowered decision‑makers who effectively communicate back to their functions. Keep the Core Team lean; leverage the Extended Launch Team to involve additional functions without slowing down execution. The Steering Committee plays a critical role by resolving escalations and making timely decisions that cannot be addressed within the Core Team, Extended Team, or individual functions.

    4) Define Roles and Ways of Working to Enable Alignment and Decision‑Making 

    Roles and responsibilities should be clearly defined across all governance groups. Equally important is aligning on ways of working early—how decisions will be made, how escalations will be handled, how information will be shared, and what each governance member is accountable for.

      Planning your next launch? 

      Building the right team and governance model is just the beginning. Whether you’re launching for the first time or bringing deep experience to a new organizational or market context, our workshop offers actionable insights, proven best practices, and practical tools to set you up for success.

      Join us on March 26th and 27th and learn from our team of launch experts. Reserve your spot today: http://bit.ly/4eP0153 or reach out to our experts here.

      Insights

      Biotech Goal Setting: Why It’s a Mistake to Wait for the Board Meeting

      We hear it all the time in biotech goal setting: “We can’t set goals until the Board signs off on our corporate strategy.”

      The problem? That board meeting often doesn’t happen until February. By then, you’ve lost two of your twelve months and momentum.

      At Danforth Health, we’ve worked with more than 1,8000 life science companies. One of the most common missteps we see is delaying biotech goal setting until everything is “finalized”. This hesitation leads to operational drift and signals to your team that alignment and accountability are negotiable. They aren’t.

      Start Early. Adjust Later.

      Even if your corporate strategy isn’t finalized yet, you can, and should, begin laying the groundwork for effective goal setting in biotech well before the calendar flips to January. 

       “You can always adjust. You can always modify. But if you wait to begin until everything is finalized, you’ve already fallen behind.” Danforth Advisors HR Experts 

      A Rolling Approach to Biotech Goal Setting

      Begin in December: Host departmental and individual goal-setting sessions using current KPIs, performance metrics, and known priorities. This helps create momentum while keeping teams focused. 

      Use a Rolling Framework: When corporate goals are finalized post-board meeting, refine existing goals- don’t restart the process. This prevents duplication of effort and supports better alignment. 

      Train Managers to Guide the Process: Not everyone is naturally skilled at facilitating effective goal-setting conversations. And in biotech, where teams are lean and leaders wear many hats, that matters. Invest in manager enablement so that goal conversations are structured, consistent, and clear.  

      “A lot of the conversations we see around goal setting are vague. You want clarity on outcomes, not just tasks. Managers need to know how to distinguish between the two.” – Danforth Advisors HR Experts 

      Best Practices for Biotech Goal Setting

      Use SMART Goals: Make them Specific, Measurable, Achievable, Relevant, and Time-bound. In biotech, metrics matter- especially when tied to funding, product development, and hiring plans. 

      Limit Company-Wide Goals to 3–5: Especially at the early stage, less is more. Trying to pursue too many priorities dilutes focus. Danforth Health consistently sees better execution when companies narrow down to a handful of core, high-impact goals. 

      Distinguish Goals from Tasks: A goal is a measurable outcome (e.g., “Complete IND submission by Q3”). A task is a step toward that goal (e.g., “Draft protocol outline”). Confusing the two can muddy accountability and derail timelines. 

      Cascade and Align: Once corporate goals are in place, ensure every department and employee understands how their work contributes to the larger mission. Alignment isn’t automatic- it’s built through communication and iteration.  

      What Happens After You Set Goals?

      Effective biotech goal setting doesn’t stop once objectives are written down. Make it a living process:

      • Revisit them monthly or quarterly 
      • Identify gaps, changing priorities, or resource constraints 
      • Adjust without starting from scratch 
      • Review progress transparently with leadership and staff 

      Need Help Setting Goals in Biotech?

      At Danforth Health, we help biotech companies operationalize clarity-turning strategic priorities into measurable, achievable goals at every level. Don’t let the calendar or boardroom delay your momentum. Reach out today. 

      Insights

      Mastering CRO Selection in 2026: A Biotech’s Strategy for Lower Risk and Better Outcomes 

      Insights by Rene Stephens, Managing Director, Danforth Advisors, a Danforth Health Company 

      As we dive into 2026, the stakes for biotech development have never been higher, and a disciplined CRO selection strategy for biotechs has shifted from a competitive advantage to a survival requirement. Capital markets remain unpredictable, the pharma patent cliff continues to reshape partnership dynamics, and regulators are increasing scrutiny around vendor oversight, data integrity, and AI-enabled trial technologies. 

      At the same time, CROs are navigating consolidation, capacity fluctuations, and geopolitical pressures, creating new execution risks even for well-prepared sponsors. In this environment, selecting the wrong CRO can derail entire programs, jeopardize valuation, and undermine investor confidence. That’s why more biotechs are partnering with outsourcing experts who bring data-driven frameworks, real-time market visibility, and negotiation power to one of the most consequential decisions in drug development. 

      Why Engage Outsourcing Experts Now 

      Navigate the Transformed CRO Landscape 

      • Assess rapidly consolidating global players and their post-M&A service quality 
      • Evaluate emerging regional CROs responding to geopolitical shifts and supply chain diversification 
      • Identify niche providers with specialized therapeutic expertise 
      • Distinguish CROs truly investing in AI/ML capabilities from those simply marketing them 
      • Track financially stable providers amid industry volatility 

      Maximize Capital Efficiency (Still Non-Negotiable in 2026) 

      • Extract maximum value from every development dollar with follow-on funding still uncertain 
      • Leverage real-time CRO pricing intelligence as the market recalibrates 
      • Negotiate favorable terms despite limited leverage in a constrained vendor ecosystem 
      • Structure flexible payment terms aligned with funding milestones and runway 
      • Utilize creative deal structures (risk-sharing, milestone-based payments) as CROs compete for quality projects 

      De-Risk in a Zero-Margin Environment 

      • Apply rigorous evaluation processes when the timeline slips or trial failures are unaffordable 
      • Identify red flags in operational capacity—resource constraints remain widespread 
      • Assess vendor financial stability as some CROs continue to face economic pressures 
      • Build contractual protections against geopolitical risk and supply chain disruptions 

      Secure Strategic Contract Terms 

      • Performance accountability: SLAs with meaningful consequences for delays 
      • Financial protections: Milestone payments, earn-backs, and sponsor-friendly advance structures 
      • Flexibility: Clear change order processes to prevent scope creep 
      • Personnel commitments: Lock in key team members to avoid bait-and-switch scenarios 
      • Termination rights: Sponsor-favorable terms given the asymmetric risk profile 
      • Rate caps: Protection against inflation and arbitrary cost escalations 

      Access Real-Time Market Intelligence 

      • Know which CROs are hungry for work vs. operating at capacity 
      • Track regulatory enforcement trends affecting timelines and budgets 
      • Navigate decentralized/hybrid trial models and supporting technologies 
      • Evaluate vendor experience with current FDA/EMA expectations and evolving guidances 

      Optimize Internal Resources 

      • Free clinical operations teams to focus on execution rather than vendor management 
      • Avoid learning-curve mistakes that resource-constrained teams cannot afford 
      • Accelerate decision-making when speed-to-clinic determines competitive position 
      • Maintain objectivity and avoid legacy or relationship-based CRO decisions 

      Leverage True Negotiating Power 

      • Benefit from outsourcing experts’ market volume and relationships 
      • Access pattern recognition from hundreds of CRO negotiations 
      • Reduce legal spend through streamlined expert-led negotiations 

      A Modern CRO Selection Strategy for Biotechs Is No Longer Optional 

      In a year defined by operational risk, regulatory pressure, and intense competition for high-quality vendors, having a rigorous CRO selection strategy for biotechs is essential. Small biotechs must execute flawlessly with limited capital and compressed timelines. 

      You can’t afford to learn CRO selection through trial and error. 

      Danforth Health’s seasoned experts can help you make selection and contracting decisions that protect your program, preserve your capital, and position you for success. Contact our team today.  

      Insights

      If You’re Going to JPM, Make it Count.

      Breaking Bad Biotech: Practical Advice for Highly Effective Biotech Organizations

      Expert insights from Gregg Beloff, Co-Founder and Managing Director of Danforth Health.

      If you’ve ever been to the JP Morgan Healthcare Conference, you know it’s less a conference and more a Jungleland – a place where the hopeful and the hardened all show up looking for a breakthrough. The energy is electric, the pace is relentless, and every conversation feels like it could change your company’s trajectory.

      But from a CFO’s chair, it’s also something else: an enormous investment. Flights, hotels, receptions, prep work, opportunity cost — the tab adds up fast. If you’ve decided to attend, you must make the investment count.

      JPM can be one of the highest-ROI weeks of your year or an expensive blur that drains both capital and focus. The difference lies in your purpose and your planning.

      Treat JPM like a strategic investment

      Think of JPM as an asset class in your annual operating plan. Before spending a dollar or booking a meeting, define what success looks like in measurable terms.

      Start by defining your objectives: are you raising capital, building partnerships, or increasing visibility ahead of a milestone? Each goal requires a different playbook and different KPIs. For example:

      • Investor ROI: How many qualified, decision-making investors will you meet?
      • Partnership traction: Which BD conversations could realistically lead to follow-up diligence?
      • Visibility return: Which events or moments get your story in front of the right audiences?

      Just like any investment, JPM needs a thesis and a disciplined approach to executing it.

      Focus on Yield, Not Volume

      It’s easy to fall into the JPM trap of equating busy with productive. Back-to-back meetings look impressive on paper, but not all of them will actually move the needle.

      The best outcomes derive from fewer, more strategic conversations that align with your financing or partnering objectives.

      • Vet every meeting: Is this a potential investor, or an information-gathering analyst?
      • Confirm who’s actually attending: decision-maker or screener?
      • Leave room for recalibration and reflection: time is capital, too.

      The week’s real winners are rarely the busiest people in the lobby. They’re the ones whose calendars were curated with purpose.

      Manage the Signal-to-Noise Ratio

      JPM week is chaos: receptions stacked on panels stacked on hallway introductions. Ask yourself:

      • Which events actually align with your company’s capital or BD strategy?
      • Where will your CEO or CBO’s time have the greatest multiplier effect?
      • What can wait for quieter weeks, when inboxes and attention spans have cleared?

      Think portfolio theory: not every opportunity deserves investment.

      Make every dollar work harder

      Treat JPM the way you’d approach any capital-intensive project — with discipline and intent.

      • Craft a crisp narrative: Tie your science to your strategy and your strategy to value creation. Investors should understand your story in two minutes flat.
      • Pre-plan your follow-ups: Don’t just “circle back.” Assign accountability for post-conference momentum.
      • Invest in presence wisely: Sometimes being seen in the right room creates more value than being everywhere at once.

      Efficiency isn’t about doing less. It’s about ensuring every dollar and every hour generates tangible returns.

      Close the loop

      After JPM, debrief like you would after closing a financing round.

      • What relationships advanced your fundraising or partnership goals?
      • What intel will shape your capital or communications strategy?
      • Did the outcomes justify the spend?
      • What are the follow-ups/next steps, and who is accountable?

      Treating JPM as a measurable investment — rather than an annual ritual — is how you turn noise into signal and activity into results.

      The Bottom Line

      In biotech, every decision is an investment — of time, attention, and capital. Treat JPM with the same financial discipline and focus you’d apply to any major investment. In a place where everyone’s chasing opportunity, the companies that win are the ones that plan, measure, and execute with purpose and intent.

      Learn more about Danforth Health and connect with our expert team.

      Insights

      Talent Gaps & Layoffs in Biotech: Navigating the New Reality

      Over the past two years, the biotech sector has weathered a difficult correction. Funding constraints and pipeline reprioritizations have led to waves of layoffs, creating leaner teams across the industry. Yet even as companies downsize, the need for specialized expertise has never been greater. The result is a widening talent gap – one that threatens productivity, continuity, and innovation.

      Leaders at small and mid-sized biotech companies are being forced to make tough decisions: how to preserve institutional knowledge, sustain development momentum, and remain competitive with limited internal bandwidth.

      Here are five takeaways for companies navigating this new workforce landscape:

      1. Prioritize Core Expertise, Outsource the Rest

      Not every role needs to be rebuilt internally. Identify which functions are critical to your intellectual property, regulatory strategy, or investor value story – and consider trusted external partners for everything else. Strategic outsourcing can allow you to execute on your business strategy while preventing burnout, reducing fixed costs, and ensuring continuity through development inflection points.

      2. Reassess Organizational Design for Agility

      Lean doesn’t have to mean overextended. Reassess how decisions have been made and consider if a smaller team could mean a more efficient approach, where bottlenecks exist, and which functions are duplicative. Flattening structures and empowering cross-functional project leads can help maintain momentum even with smaller teams.

      3. Invest in Retention – Even When You’re Cutting Costs

      After layoffs, there is often undesirable attrition, and the remaining team members often carry heavier workloads and higher stress. Retention depends on transparency, recognition, and growth opportunities. Simple actions, like reviewing and updating roles and responsibilities,  consistent communication about company direction, flexible work arrangements, or development stipends, can have an outsized impact on morale and loyalty.

      4. Bridge Skill Gaps Through Partnerships and Interim Talent

      Specialized expertise in areas like regulatory strategy, CMC, bioinformatics, and clinical operations is increasingly scarce. Interim or fractional experts can bridge capability gaps without the long-term cost of full-time hires, allowing your team to have the right level and amount of expertise as needed. If you are embracing a fractional model, look for experienced consultants or partner firms who understand biotech’s unique regulatory and operational nuances.

      5. Revisit Workforce Planning Every Quarter

      Embrace a just-in-time hiring model. While there is great talent in the market right now, hiring too far ahead of your needs can unnecessarily accelerate your cash burn. The market is shifting fast. What seemed essential six months ago may not be today. Building a rolling 3- to 6-month talent roadmap—aligned with your pipeline milestones and financing horizon—helps avoid reactionary hiring or deep cuts later on.

      The Bottom Line

      The biotech talent landscape is being reshaped in real time, but the need for great talent never goes away. In today’s environment, success will depend on strategic resourcing, organizational agility, and empathetic leadership. Companies that balance cost discipline with a thoughtful approach to people management will emerge stronger, more focused, and ready to capture opportunity as the market rebounds.

      Danforth Health uniquely bridges both sides of the talent challenge — providing fractional experts to fill critical functional gaps. Our team can work with you to determine if a fractional resource is right for your business or if this is the time to invest in a full-time hire. Either way, we have the expertise and network to assess your needs, recruit the appropriate resources, and support their onboarding in a way that thoughtfully integrates them into your team quickly and efficiently.

      Click here to schedule a free consultation about how we can support your talent needs.

      Insights

      Finding your people: effective HR strategy for early-stage biotech 

      HR is more than just an administrative function; it’s a critical strategic tool, especially for early stage biotech companies.  

      But why is HR strategy so important for early-stage biotechs in particular? And how can you craft a HR strategy that fosters scientific discovery, helps you scale, and keeps you competitive?  

      HR challenges in early-stage biotech: 

       Early-stage biotechs face a unique set of obstacles. Perhaps the most pertinent are:  

      • Scarcity of specialized talent. A limited pool of candidates for highly technical scientific roles means securing talent is hard and can quickly drain precious capital.  
      • The need to balance operational efficiency with scientific risk-taking. Biotech companies must create a culture that fosters intelligent risk-taking and creativity while also ensuring that business operations remain efficient and focused. Creating a culture that encourages experimentation while maintaining a practical, results-driven environment, though, is tough.  

      To address these challenges and set the foundation for long-term success, biotech companies can’t simply rely on traditional hiring practices. They need a well-crafted HR strategy that is tailored to these obstacles and adapts to evolving needs.  

      So, what does that look like? 

      Attracting scarce, specialized talent with limited resources: 

      With biotech companies often unable to offer the competitive salaries needed to secure the best and brightest talent, they must rely on more creative approaches, such as:  

      • Offering equity compensation. Offering ownership stakes can help attract talent with the promise of long-term success despite cash restraints.  
      • Using flexible hiring models. Companies that are priced out of full-time roles should consider part-time experts and consultants to gain specialized expertise without committing to large, fixed costs.  
      • Leveraging founders’ networks. Identifying specific talent through existing connections, rather than working with recruiters, can cut costs on the search for new candidates, too.   

      By using these strategies cash-strapped biotech companies have the best chance of building winning teams while preserving their capital.  

      Encouraging scientific risk-taking while protecting operational efficiency: 

       As noted above, success in biotech demands a supportive space for productive risk-taking and failure, while still keeping operations efficient.  

       Key practices include: 

      • Creating a culture that celebrates scientific rigor while accepting failure as an unavoidable part of drug development. 
      • Hiring people who understand both the scientific and the business realities of biotech. 
      • Facilitating and maintaining open communication between scientific and operational teams. 
      • Developing a hiring strategy that evolves with the company to maintain the right balance of operational oversight and scientific innovation  

      “Creating an environment where the team can safely experiment and learn from failures is key. We used to hold funerals for projects. It was cathartic and showed our teams that we want them to take risks. If you are going to fail, fail fast and learn from it—let it inform your science.” —Gregg Beloff, Co-Founder and Managing Director, Danforth Advisors, a Danforth Health company. 

      Building a fit-for-purpose HR strategy for today and beyond: 

      Building a strong HR foundation is key to navigating the complexities you’ll face as an early-stage biotech company, from attracting top talent to fostering a culture that balances risk-taking with commercial viability.   

      But securing a winning team amid talent shortages and building an innovation-friendly culture are just two of myriad HR challenges an early-stage biotech will face.   

       What’s more, as biotech companies scale, those challenges morph and evolve into a different beast altogether, demanding more comprehensive and nuanced HR support.   

      Find out more about those challenges and how best to navigate them, by connecting with our HR experts. Reach out to our team today.  

      Insights

      Clinical Trial Financial Management: A Practical Guide for Biopharma Professionals 

      Insights From an Expert: Written by Rene Stephens, Managing Director, Danforth Advisors, a Danforth Health Company

      Why Clinical Trial Financial Management Matters 

      Running a clinical trial isn’t just about patient visits and data collection; it’s also about making sure the financial management side runs smoothly. When finances get messy, it can slow down the science, frustrate leadership, and create stress for the teams doing the work. This guide is built for you: those on the front lines making sure Clinical Operations, Finance, and Procurement stay in sync. We’ll break down how a strong clinical trial financial management process can make your job easier, keep budgets on track, and avoid last-minute surprises. 

      Caught Between an Invoice and a Hard Place 

      In clinical trials, timelines change, patient enrollment slows down (or speeds up), and site invoices don’t always show up when you expect them. The problem? Finance needs accurate numbers now, Clinical Ops needs the flexibility to adjust plans, and vendors have their own schedules. Without a financial management system that ties all this together, things slip through the cracks, and that’s when costs creep up. 

      The Three Big Things to Get Right in Clinical Trial Financial Management 

      1. Accurate & Timely Tracking: You can’t fix what you can’t see. Track real activity (patients, site activations, visits) and tie it directly to spend. 
      1. Proactive Risk Spotting: Look for signs that costs might run over: delayed site openings, slower enrollment, or CRO scope creep. 
      1. Clear Communication: Make sure Clinical Ops, Finance, and Procurement are speaking the same language and sharing the same data. 

      How to Put Clinical Trial Financial Management into Action 

      Here’s the good news: you don’t need to reinvent the wheel. Danforth’s methodology and fit-for-purpose tools give you a monthly rhythm that keeps everyone aligned: 

      • Gather real study activity data from Clinical Ops (EDC reports, site status, enrollment projections). 
      • Pull vendor and CRO cost updates. 
      • Compare what’s been done to what’s been billed. 
      • Update forecasts so Finance sees the real picture, not just invoices. 
      • Review as a team so everyone’s on the same page before numbers go to leadership. 

      Avoid These Common Headaches 

      1. Relying only on supplier reports: Vendors don’t always have the same view of your budget priorities. 
      1. Late or missing site invoices: This can throw off accruals and make Finance chase numbers. 
      1. Forecasts disconnected from reality: If your forecast is based on the original plan, but enrollment has shifted, it’s already outdated. 

      What This Looks Like in Practice 

      • Saving $350K in CRO Advances: A sponsor was about to hand over a huge upfront payment to a CRO. We helped cut that in half and spread the payments over time, freeing up cash for other priorities. 
      • Fixing Forecast Accuracy: We spotted a patient timeline issue in a CRO report, updated the forecast, and avoided a major budget miss. 
      • Cleaning Up Investigator Payments: By tracking from the EDC instead of CRO pass-through estimates, we improved accrual accuracy and avoided month-end surprises. 

      Practical Tips for Better Financial Oversight 

      1. Have a single shared file or dashboard that Finance, Clinical Ops, and Procurement can all use. 
      1. Keep a monthly checklist so nothing gets missed, especially vendor updates and site activity data. 
      1. Flag big changes early; leadership likes solutions, not surprises. 
      1. Document decisions: when the audit comes, you’ll be glad you did. 

      The Bottom Line 

      You’re the bridge between the science and the numbers. Strong clinical trial financial management keeps trials on budget, provides leadership with the insights they need, and makes your role less stressful. It’s about building habits, using the right tools, and keeping the conversation going across teams.   

      Need help improving your clinical trial financial processes? Danforth Health specializes in financial planning, forecasting, and vendor oversight for biopharma companies. Contact us today to get started. 

      Insights

      The Three Essentials of Effective Biotech Change Management Communication 

      In any biotech change management project, one element consistently determines whether the process succeeds or stalls: how you communicate with your people. 

      Many leaders put significant energy into designing the change itself: the strategy, the timelines, and the operational details. But when it comes to telling the story of that change, they falter. 

      Sometimes it’s because they assume everyone is already on board. For example, during periods of biotech growth, leadership may think the company’s upward trajectory speaks for itself. They may believe morale is high enough to carry the change forward without a structured communications plan. 

       It’s an innocent assumption… and it can be an expensive one. 

      The Danger of the Information Void 

      If employees aren’t given a clear, transparent view of what’s happening during a time of change, they will fill in the blanks themselves. And in times of uncertainty, those stories are often negative. 

      An impactful change management communication plan answers three core questions for employees: 

      1. The What 

      Spell out the change with precision. Avoid vague statements like “We’re restructuring” or “We’re improving workflows.” These broad phrases leave too much room for speculation. Specificity creates clarity, and clarity prevents harmful narratives from taking hold. 

      2. The Why 

      The rationale behind a change is as important as the change itself. Why this change? Why now? Why in this particular way? People are more motivated when they understand the reasoning and can connect it to a tangible benefit for the organization, their team, or themselves. 

      3. The How and Impact 

      Explain the steps that will bring the change to life and outline the effects on both the business and each individual. When people know what to expect, uncertainty fades and trust grows.  

      Honoring the Individual 

      Effective change management communication goes beyond processes and timelines. It’s also about acknowledging the human side of change. 

      When you explain the impact at the individual level: “Here’s how this will affect your role, your day-to-day work, and your opportunities going forward” you show that you’ve thought about them, you understand their contribution, and you value it. 

      As our experts say, “Be granular when explaining the impact of the change to individuals. This shows that the company has thought about the person, knows what they do and values their contribution. This is about honoring the individual.”  

      Is your organization facing the complexities of change management?  

      Danforth Health has supported numerous life science companies through the intricacies and sensitivities of change management. Contact our team today.